Pubertal Blockade and Hormone Therapy in Transgender Youth (PUBErTY)

Effects of Pubertal Blockade and Hormone Therapy on Cardiometabolic Risk Markers in Transgender Adolescents

This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness, mitochondrial function and the microbiome.

Study Overview

• Status: Completed
• Conditions: Gender Dysphoria; Gender Identity; Gender Identity Disorder in Adolescence and Adulthood

Detailed Description

There will be a total of 6 study visits: baseline A, baseline B, 1 month after starting testosterone (visit A and B) and 12 months after starting testosterone (visit A and B). No medications will be administered as a part of this study.

Visit A procedures: Physical Examination, Laboratory, and Oral Glucose Tolerance Test (OGTT) visit.

This will be conducted at Childrens Hospital Colorado (CHCO) Clinical & Translational Research Centers (CTRC) facilities. Physical examination will include vital signs, anthropometric measurements, and breast/pubic hair staging as applicable (some subjects may have already undergone mastectomy/chest masculinizing surgery) by the PI. Subjects will fast for 8 hours prior to blood draw. Fasting blood work will be obtained, followed by an oral glucose load (75g glucola). Blood glucose and insulin concentrations will be drawn at baseline and 30, 60, 90 and 120 minutes after glucola administration. Serum will be obtained at baseline and 2 hours post-OGTT and used for bile acid and lipid metabolomic profile. The following questionnaires will be administered: REDCap Health Questionnaire, PedsQLTM 4.0 generic core questionnaire, PROMIS Pediatric Anxiety Short Form, PROMIS Pediatric Depressive Symptoms Short Form, Insomnia Severity Index, Morningness and Eveningness Scale. Participants will be mailed or emailed the 3-day dietary log prior to the visit and return it at this visit. They will be given a stool microbiome collection kit and urine collection kit to return at visit B. The medical chart will be reviewed for relevant health information and medications.

Part B: Vascular Imaging, MR-based imaging and spectroscopy, Exercise Capacity and Dual-energy X-ray (DXA) visit.

This will be conducted at the University of Colorado Denver Energy Balance Core and UCD Brain Imaging Center. The participant will be fasting for a minimum of 4 hours prior to the beginning of the study visit. The investigators will perform the tests in the following order:

1. Participants will return stool microbiome and urine collection kit.
2. Vascular imaging: carotid artery stiffness and intimal medial thickness and brachial artery flow-mediated dilation
3. Magnetic Resonance (MR) based imaging and spectroscopy
4. Oxygen consumption (VO2) peak exercise test on a stationary bicycle.
5. Total body dual energy x-ray absorptiometry (DXA)
6. Participants will be provided with an accelerometer and actigraphy watch to wear for a period of 7 days to measure level of habitual physical activity and sleep, respectively. They will also be provided a handout with instructions and a sleep and activity diary to be filled out each day during the 7 days of wear.

• Study Type: Observational
• Enrollment (Actual): 19

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Children's Hospital Colorado

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 11 years to 14 years (Child)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

16 female-to-male youth will be enrolled from 2 groups: 1) 8 female-to-male youth who have been on a gonadotropin-releasing hormone analogue for > 6 months; 2) 8 female-to-male (age-matched) youth who never received gonadotropin-releasing hormone analogue therapy.

Description

Inclusion Criteria:

• Identify as female-to-male
• Age 13-16 years at the time of enrollment
• If on a gonadotropin-releasing hormone analogue, > 6 months exposure
• Plan to start testosterone clinically in < 6 months.

Exclusion Criteria:

• Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
• Diabetes
• Antipsychotic medication
• Hypertension (resting BP ≥ 140/90 mm/Hg)
• Weight > 400 lbs (DXA and MRI limit)
• On estrogen and/or progesterone medications

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
On a GnRHa; Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
Not on GnRHa; Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Insulin sensitivity	Assessed by the Matsuda index, calculated from a 2-hour oral glucose tolerance test	Baseline and 12 months after initiation of testosterone.
Change in Vascular Health	Brachial artery flow-mediated dilation	Baseline and 12 months after initiation of testosterone.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Mitochondrial function	Hepatic mitochondrial function as assessed by 31Phosphorus- Magnetic Resonance Spectroscopy	Baseline and 12 months after initiation of testosterone.
Change in VO2 peak	VO2 peak as measured on a bicycle ergometer	Baseline and 12 months after initiation of testosterone.
Change in Body composition	as measured on a Dual-energy X-ray Absorptiometry (DXA) scan	Baseline and 12 months after initiation of testosterone.

Collaborators and Investigators

• Sponsor: University of Colorado, Denver

Study record dates

Study Major Dates

• Study Start (Actual): June 19, 2018
• Primary Completion (Actual): September 9, 2020
• Study Completion (Actual): September 9, 2020

Study Registration Dates

• First Submitted: May 8, 2018
• First Submitted That Met QC Criteria: June 13, 2018
• First Posted (Actual): June 14, 2018

Study Record Updates

• Last Update Posted (Actual): September 29, 2020
• Last Update Submitted That Met QC Criteria: September 28, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Sexual Dysfunctions, Psychological; Gender Dysphoria
• Other Study ID Numbers: 17-2328

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No